2-(((3aR,4S,6R,6aS)-6-((5-Amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol is a Ticagrelor-related pharmaceutical intermediate
2-(((3aR,4S,6R,6aS)-6-((5-Amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol is a Ticagrelor-related pharmaceutical compound identified in chemical reference catalogues as Ticagrelor Related Compound 17 and Ticagrelor Intermediate 12.
This compound contains a substituted aminopyrimidine group, a propylthio side chain, and a stereochemically defined oxygen-containing cyclic structure. It is relevant to pharmaceutical research, analytical characterization, and Ticagrelor-related compound evaluation.
Handle the material in accordance with its current Safety Data Sheet (SDS) and applicable workplace chemical safety procedures.
This compound is a Ticagrelor-related chemical compound and should not be assigned the therapeutic activity of Ticagrelor without supporting evidence.
Ticagrelor, the associated active pharmaceutical ingredient (API), is a reversible P2Y12 adenosine diphosphate (ADP) receptor antagonist. It inhibits ADP-mediated platelet activation and aggregation, helping reduce thrombotic cardiovascular events in appropriate clinical settings.
The mechanism of action of CAS 376608-74-1 as an isolated compound is not established as a standalone therapeutic mechanism.
CAS No. 376608-74-1 identifies a Ticagrelor-related compound also listed by chemical suppliers as Ticagrelor Related Compound 17 and Ticagrelor Intermediate 12.
Its molecular formula is C₁₇H₂₇ClN₄O₄S.
The molecular weight is approximately 418.94 g/mol.
No. It is a distinct Ticagrelor-related compound and must not be treated as interchangeable with the finished Ticagrelor API.
Potential applications include pharmaceutical research, analytical characterization, impurity evaluation, and related process-development activities, depending on the intended grade and supporting documentation.
Product-specific documentation may include identity, assay or purity, appearance, related substances, and other agreed quality parameters. Confirm the available specifications against the current batch CoA.
Use appropriate personal protective equipment, minimize dust exposure, and follow the current SDS for handling, storage, first aid, and disposal.
Contact Chemox Pharma to enquire about product availability, sample quantities, commercial terms, and applicable technical documentation.
Depending on availability, relevant documents may include a batch CoA, SDS, product specification, and other quality documentation agreed with the customer.
Follow the storage conditions stated in the current supplier SDS and approved product specification. Do not apply a generic storage temperature without confirming the requirements for the supplied batch.
5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole is a benzimidazole-based pharmaceutical intermediate used in the synthesis of Pantoprazole and related pharmaceutical compounds. Its chemical structure contains a difluoromethoxy
(R)-2-(2-Aminothiazol-4-yl)-N-(2-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide is a structurally related compound associated with Mirabegron and is also identified in chemical references as ortho-Mirabegron. This compound may be
R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide is a chiral pharmaceutical intermediate associated with the synthesis of Mirabegron. It contains a stereochemically defined hydroxyphenylacetamide structure and a nitrophenethyl
